RAMM Pharma Corp. Provides Update on Canada post strike and mailing of the Company´s meeting materials

Rhea-AI Summary

RAMM Pharma (CSE: RAMMF) notified shareholders on Oct 22, 2025 that Canada Post strike disruptions may delay delivery of proxy and meeting materials for the Special Meeting of Shareholders on Nov 12, 2025 at 2:30 p.m. Toronto time.

The Meeting Materials are available electronically on SEDAR+ and via Odyssey Trust at https://odysseytrust.com/client/ramm-pharma-corp-spc/. While materials were mailed, delivery before the meeting is not assured due to partial mail service and potential delays.

Registered shareholders can request a control number or voting help via Odyssey Trust’s chat or by calling 1-888-290-1175 (North America toll-free) or 1-587-885-0960 (outside North America). Beneficial shareholders should contact their brokerage or intermediary to request a proxy.

TORONTO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), wishes to notify shareholders that a disruption due to the ongoing Canada Post strike (the “Postal Strike”), and the recent update that mail will resume partial service, but there may still be delays, the Company’s meeting materials (the “Meeting Materials”) for the Company’s upcoming Special Meeting of Shareholders to be held on November 12, 2025 at 2:30 p.m. (Toronto Time) (the “Meeting”) , may be viewed on the Company’s SEDAR+ profile at www.sedarplus.ca and are also available electronically at https://odysseytrust.com/client/ramm-pharma-corp-spc/.

While the Meeting Materials have been mailed in the normal course, due to the uncertainty of normal Postal Service there can be no assurance that they will be delivered prior to the Meeting.

Registered shareholders, shareholders who hold their shares directly in the Company and not through a brokerage account or other intermediary, may request a control number or receive assistance with voting by utilizing the “Chat with Odyssey Trust” function at https://odysseytrust.com/contact/ or by contacting Odyssey Trust Company at 1-888-290-1175 (toll-free in North America) or at 1-587-885-0960 (direct from outside of North America).

Beneficial shareholders, shareholders who hold their investment through a brokerage firm or other intermediary, and have not received their information, should contact their intermediary to request a proxy.

About RAMM Pharma Corp.

RAMM Pharma is active in the field of cannabinoid pharmacology and product formulation for cannabis and other hemp-based products with a diversified international production and sales platform.

In Europe, RAMM's vertically integrated operations are based in Ragusa, Italy and Elbląg, Poland (60 kilometres east of Gdańsk), and include large extraction and processing facilities (in the case of Canapar Corp. which is a subsidiary of the Company). Hempoland is a licensed producer, contract manufacturer and distributor of hemp products, including CannibiGold-branded products and other white and private label products. RAMM Pharma includes wholly owned subsidiaries Canapar Corp., HemPoland Sp. Z o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

Additional information about the Company is available at www.wearerammpharma.com.

For further information, please contact:

José Roldan
Interim CFO
+598 99 057 301
jroldan@rammpharma.com

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, the Company’s strategies and objectives, and future expansion plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: the resolution of the litigation that Ramm is pursuing and defending; financial risk in connection with the litigation; the amount accrued in the Company’s financial statements in respect of the litigation; future growth potential of the Company; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Uruguayan, Latin American, European and international medical and recreational cannabis markets and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Uruguay or internationally; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

FAQ

When is RAMM Pharma's Special Meeting of Shareholders (RAMMF)?

The Special Meeting is scheduled for Nov 12, 2025 at 2:30 p.m. Toronto time.

Where can I view RAMM Pharma (RAMMF) meeting materials online due to Canada Post delays?

Meeting materials are available on SEDAR+ and at https://odysseytrust.com/client/ramm-pharma-corp-spc/.

What should registered RAMM Pharma (RAMMF) shareholders do if they haven't received mailed materials?

Registered shareholders can request a control number or voting help via Odyssey Trust chat or by calling 1-888-290-1175 or 1-587-885-0960.

What should beneficial RAMM Pharma (RAMMF) shareholders do if they haven't received proxy information?

Beneficial shareholders should contact their brokerage or intermediary to request a proxy and voting instructions.

Does RAMM Pharma (RAMMF) guarantee mailed meeting materials will arrive before the Nov 12, 2025 meeting?

No; the company cautioned that mail disruptions mean there is no assurance materials will be delivered before the meeting.

How can I contact Odyssey Trust for RAMM Pharma (RAMMF) voting assistance outside North America?

Call Odyssey Trust at 1-587-885-0960 for direct assistance from outside North America.